Skip to content
Back to KPTIQ

Karyopharm Therapeutics Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
21
Purchases
0
Sales
21
Purchase value
$0.00
Sale value
$351.41K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Kristin AbateChief Accounting Officer
4
Filed Oct 19, 2026Period of report Oct 16, 20260001193125-26-425227
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 16, 2026
Common StockF14,788$0.344$1.65K18,616Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Kristin AbateChief Accounting Officer
4
Filed Oct 2, 2026Period of report Oct 1, 20260001193125-26-412209
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 1, 2026
Common StockF1378$1.19$449.8223,404Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Kristin AbateChief Accounting Officer
4
Filed Sep 2, 2026Period of report Sep 1, 20260001193125-26-380404
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 1, 2026
Common StockF119$2.02$38.3823,782Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Stuart PoultonEVP, Chief Development Officer
4
Filed Jul 30, 2026Period of report Jul 28, 20260001193125-26-326290
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 28, 2026
Common StockF1189$7.10$1.34K94,632Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Stuart PoultonEVP, Chief Development Officer
4
Filed May 15, 2026Period of report May 13, 20260001193125-26-226697
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 14, 2026
Common StockF2403$9.50$3.83K94,821Direct
Filing footnotes · 2
  1. F1Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
  2. F2This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Reshma RangwalaEVP & Chief Medical Officer
4
Filed May 15, 2026Period of report May 13, 20260001193125-26-226685
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 14, 2026
Common StockF2408$9.50$3.88K56,829Direct
Filing footnotes · 2
  1. F1Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
  2. F2This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Sohanya Roshan ChengEVP & Chief Commercial Officer
4
Filed May 15, 2026Period of report May 13, 20260001193125-26-226652
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 14, 2026
Common StockF2324$9.50$3.08K107,940Direct
Filing footnotes · 2
  1. F1Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026.
  2. F2This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Kristin AbateChief Accounting Officer
4
Filed May 15, 2026Period of report May 13, 20260001193125-26-226616
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 14, 2026
Common StockF353$9.50$503.5023,801Direct
Filing footnotes · 3
  1. F1Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
  2. F2Includes 1,670 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan, as amended, on April 30, 2026.
  3. F3This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Richard A. PaulsonDirector · President and CEO
4
Filed May 15, 2026Period of report May 13, 20260001193125-26-226613
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 14, 2026
Common StockF22,203$9.50$20.93K269,747Direct
Filing footnotes · 2
  1. F1Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
  2. F2This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Michael ManoEVP, CLO&Secretary
4
Filed May 15, 2026Period of report May 13, 20260001193125-26-226604
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 14, 2026
Common StockF2266$9.50$2.53K94,398Direct
Filing footnotes · 2
  1. F1Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
  2. F2This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Reshma RangwalaEVP & Chief Medical Officer
4
Filed Apr 22, 2026Period of report Apr 21, 20260001825322-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 21, 2026
Common StockF1449$8.94$4.01K56,290Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Kristin AbateChief Accounting Officer
4
Filed Mar 3, 2026Period of report Mar 2, 20260002045943-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF1559$9.4095$5.26K22,063Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Stuart PoultonEVP, Chief Development Officer
4
Filed Mar 3, 2026Period of report Mar 2, 20260001942597-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF15,101$9.4095$48.00K94,328Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Sohanya Roshan ChengEVP & Chief Commercial Officer
4
Filed Mar 3, 2026Period of report Mar 2, 20260001865796-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF14,604$9.4095$43.32K107,317Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Michael ManoEVP, CLO&Secretary
4
Filed Mar 3, 2026Period of report Mar 2, 20260001837741-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF13,526$9.4095$33.18K93,964Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Reshma RangwalaEVP & Chief Medical Officer
4
Filed Mar 3, 2026Period of report Mar 2, 20260001825322-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF15,066$9.4095$47.67K56,739Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Richard A. PaulsonDirector · President and CEO
4
Filed Mar 3, 2026Period of report Mar 2, 20260001804460-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF112,361$9.4095$116.31K267,030Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Stuart PoultonEVP, Chief Development Officer
4
Filed Feb 19, 2026Period of report Feb 17, 20260001193125-26-059332
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 17, 2026
Common StockF1378$8.63$3.26K99,429Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Lori MacomberEVP, CFO & Treasurer
4
Filed Feb 4, 2026Period of report Feb 3, 20260001193125-26-037584
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 3, 2026
Common StockF11,626$6.30$10.24K85,105Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 19, 2024, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Kristin AbateChief Accounting Officer
4
Filed Jan 29, 2026Period of report Jan 27, 20260001193125-26-029599
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 28, 2026
Common StockF250$7.03$351.5022,622Direct
Filing footnotes · 2
  1. F1Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the revenue and total shareholder return milestones as certified by the issuer's Compensation Committee on January 27, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on January 27, 2026.
  2. F2This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR
Kristin AbateChief Accounting Officer
4
Filed Jan 22, 2026Period of report Jan 21, 20260001193125-26-019428
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 21, 2026
Common StockF1265$5.96$1.58K22,580Direct
Filing footnotes · 1
  1. F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.